CorMedix Inc (CRMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $370.64M
Last updated: Nov 17, 2026 at 11:05 AM ET
CorMedix Inc (CRMD) P/E Ratio & Valuation History
CorMedix (CRMD) trades at 6.3x trailing earnings and 0.9x sales. Its P/B of 0.8x is below its 5-year median of 3.1x. Its forward P/E is 33.2x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 81.0% lower over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 6.3x |
| Forward P/E | 33.2x |
| Price to sales | 0.9x |
| Price to book | 0.8x |
| EV/EBITDA | 1.0x |
| Price to FCF | 1.2x |
| EV/FCF | 0.5x |
| PEG | N/A |
| FCF yield | 81.4% |
Historical Medians
Against its 10-year medians, its P/B is 77.1% below 3.5x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 0.8x | 3.1x | 3.5x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 3.0x in 2025 to 891.7x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $11.63 | 5.4x | 3.0x | 2.7x |
| 2024 | $8.10 | N/A | 11.3x | 5.9x |
| 2023 | $3.76 | N/A | 709.6x | 3.1x |
| 2022 | $4.22 | N/A | N/A | 3.2x |
| 2021 | $4.55 | N/A | 888.0x | 2.8x |
| 2020 | $7.43 | N/A | 891.7x | 5.4x |
| 2019 | $7.28 | N/A | 605.7x | N/A |
| 2018 | $6.45 | N/A | 279.8x | N/A |
| 2017 | $2.50 | N/A | 83.8x | N/A |
| 2016 | $7.65 | N/A | 266.7x | 3.5x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CRMD
What is CRMD's forward P/E ratio?
CorMedix has a forward P/E ratio of 33.2x.
Is CRMD stock overvalued?
GNG's valuation label for CRMD is Undervalued.
What is CRMD's price to sales ratio?
CorMedix has a price to sales ratio of 0.9x.
CRMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors